Do you want to read an article? Please log in or register.
Clinical impact of local consolidative therapy in EGFR-mutant metastatic NSCLC: A propensity-matched multicenter analysis
Lung Cancer
Related content
Lung Cancer
First-line integration of Local Ablative Therapy (LAT) with EGFR Tyrosine Kinase Inhibitors (TKIs) in advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis
J Thorac Oncol
Brunetti L, Colella G, Di Fazio GR, La Cava G, Santo V, Pecci F, Rotow J, Bauman JR, Nassar AH, Adib E, Naqash AR, Tagliamento M, Ferrara R, Citarella F, Russano M, Ricciuti B, Faivre-Finn C, Hendriks LEL, Passaro A, Vincenzi B, Acker F, Derosa L, Planchard D, Aerts HJWL, Novello S, Passiglia F, Greco C, Ramella S, Cortellini A
doi: 10.1016/j.jtho.2026.103735
RECOMMENDED
Lung Cancer
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
Adv Ther
Girard N, Macouillard P, Byng D, Meng J, Coerts F, Hunter S, Struebing A, Xiong Y, Park S, Haq MI, Tymejczyk O, Chouaid C, Audigier-Valette C, Debieuvre D, Quantin X, Bosquet L, Pérol M
doi: 10.1007/s12325-025-03465-4
Lung Cancer
Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)
Nat Commun
Shen B, Wang C, Zhang L, Zhu Y, Zhang X, Wang X, Guo Z, Wang L, Wang X, Zhu L, Zhou Y, Liao D, Shi M
doi: 10.1038/s41467-026-68554-6
Lung Cancer
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
Lung Cancer
Zhou DD, Lord SJ, Lin FP, Cooper WA, Zaheed M, Simes RJ, John T, Lee CK
doi: 10.1016/j.lungcan.2025.108891
RECOMMENDED
Lung Cancer
Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Atlagh L, Toublanc AC, Roch B, Marinello A, Ruuth-Praz J, Cousin S, Chouaid C, Basset C, Evrard S, Duruisseaux M, Girard N, Durand K, Mazières J, Brindel A
doi: 10.1016/j.cllc.2025.06.005
RECOMMENDED
Lung Cancer
Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Lee J, Kim M, Han HJ, Kim S, Suh HS
doi: 10.1016/j.lungcan.2025.108682
Lung Cancer
Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis
J Clin Med
Çelik S, Kavak EE, Zeynelgil E, İmamoğlu Gİ, Dilli İ, Karatlı S, Atak M, Altınbaş M, Eren T
doi: 10.3390/jcm15072475
Lung Cancer
Durvalumab After Chemoradiotherapy for Locally Advanced NSCLC: A Real-World Analysis Using a Nationwide Claims Database in Japan
Clin Lung Cancer
Takeda K, Yamamoto T, Umezawa R, Takahashi N, Okuda S, Jingu K
doi: 10.1016/j.cllc.2026.05.010
Lung Cancer
Central Nervous System Outcomes of Lazertinib Treatment in EGFR-Mutated Advanced NSCLC: Pooled Analysis From LASER201 and LASER301
Clin Lung Cancer
Yang JC, Ahn MJ, Kim JH, Lee YG, Han JY, Lee KH, Zimina A, Kim DW, Lee KH, Lee SS, Lim CS, Lim YN, Min YJ, Orlov S, Lee Y, Kim Y, Kwon MJ, Lee H, Cho H, Cho BC
doi: 10.1016/j.cllc.2025.08.007